ITT Free cash flow decreased by 92.6% to $13.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 82.0%, from $76.60M to $13.80M. Over 3 years (FY 2022 to FY 2025), Free cash flow shows an upward trend with a 46.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$320.30M | -$32.70M | $39.40M | $34.80M | $132.30M | $29.40M | $122.10M | $147.60M | $131.30M | $30.10M | $134.50M | $87.30M | $186.80M | $76.60M | $137.30M | $146.20M | $187.40M | $13.80M |
| QoQ Change | — | +89.8% | +220.5% | -11.7% | +280.2% | -77.8% | +315.3% | +20.9% | -11.0% | -77.1% | +346.8% | -35.1% | +114.0% | -59.0% | +79.2% | +6.5% | +28.2% | -92.6% |
| YoY Change | — | — | +112.3% | — | — | +189.9% | +209.9% | +324.1% | -0.8% | +2.4% | +10.2% | -40.9% | +42.3% | +154.5% | +2.1% | +67.5% | +0.3% | -82.0% |